Full encapsulation of oncolytic virus using hybrid erythroctye-liposome membranes for augmented anti-refractory tumor effectiveness
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Virus-based gene therapy research · RNA Interference and Gene Delivery · Bacteriophages and microbial interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (29)
Show source-provided references
1. Oncolytic viruses as engineering platforms for combination immunotherapy10.1038/s41568-018-0009-4 ↗
2. Oncolytic viruses in cancer treatment: a review10.1001/jamaoncol.2016.2064 ↗
3. National Comprehensive Cancer Network®https://www.nccn.org.
4. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond10.1186/s13045-021-01109-y ↗
5. In situ cancer vaccination using lipidoid nanoparticles
6. Deletion of apoptosis inhibitor F1L in vaccinia virus increases safety and oncolysis for cancer therapy10.1016/j.omto.2019.06.004 ↗
7. Strategies to achieve systemic delivery of therapeutic cells and microbes to tumors10.1517/14712598.7.1.41 ↗
8. Oncolytic virotherapy10.1016/j.jvir.2013.05.040 ↗
9. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results10.1016/j.urolonc.2017.07.005 ↗
10. Cell Membrane Coating Technology: A Promising Strategy for Biomedical Applications10.1007/s40820-019-0330-9 ↗
11. Engineering of stimuli-responsive self-assembled biomimetic nanoparticles10.1016/j.addr.2021.114006 ↗
12. Cell membrane-derived vesicles for delivery of therapeutic agents10.1016/j.apsb.2021.01.020 ↗
13. Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application10.1016/j.apsb.2019.01.011 ↗
14. Oncolytic viruses: adenoviruses10.1007/s11262-017-1488-1 ↗
15. Roles of toll-like receptor 3 in human tumors
16. Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses10.1111/j.1600-065X.2007.00564.x ↗
17. Protein corona modulates interaction of spiky nanoparticles with lipid bilayers10.1016/j.jcis.2021.06.047 ↗
18. Artificially cloaked viral nanovaccine for cancer immunotherapy10.1038/s41467-019-13744-8 ↗
19. Remote loading of small-molecule therapeutics into cholesterol-enriched cell-membrane-derived vesicles10.1002/anie.201707598 ↗
20. Erythroliposomes: integrated hybrid nanovesicles composed of erythrocyte membranes and artificial lipid membranes for pore-forming toxin clearance10.1021/acsnano.8b08964 ↗
21. Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 1110.1038/mt.2011.242 ↗
22. Engineering biomimetic platesomes for pH‐responsive drug delivery and enhanced antitumor activity10.1002/adma.201900795 ↗
23. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D10.1128/JVI.02696-06 ↗
24. Genetically engineered cell membrane nanovesicles for oncolytic adenovirus delivery: a versatile platform for cancer virotherapy10.1021/acs.nanolett.9b00145 ↗
25. The progress and perspective of strategies to improve tumor penetration of nanomedicines10.1016/j.cclet.2020.11.006 ↗
26. Nanomedicine-based drug delivery towards tumor biological and immunological microenvironment10.1016/j.apsb.2020.05.008 ↗
27. The progress and perspective of nanoparticle-enabled tumor metastasis treatment10.1016/j.apsb.2020.07.013 ↗
28. The efficacy of oncolytic adenovirus is mediated by t-cell responses against virus and tumor in syrian hamster model10.1158/1078-0432.CCR-16-0477 ↗
29. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters10.1128/JVI.02127-08 ↗